Danaher (NYSE:DHR) Price Target Raised to $270.00

Danaher (NYSE:DHR) had its target price boosted by JPMorgan Chase & Co. from $250.00 to $270.00 in a research report report published on Thursday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the conglomerate’s stock.

DHR has been the topic of several other research reports. UBS Group started coverage on Danaher in a research report on Wednesday, September 9th. They issued a “buy” rating and a $250.00 price objective on the stock. Evercore reaffirmed an “outperform” rating and set a $230.00 target price on shares of Danaher in a research report on Monday, July 6th. Wells Fargo & Company decreased their target price on Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 22nd. Stifel Nicolaus lifted their target price on Danaher from $220.00 to $260.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Royal Bank Of Canada boosted their price target on shares of Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a report on Monday, October 5th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $242.91.

Danaher Price Performance

Shares of NYSE DHR opened at $230.36 on Thursday. The company has a market capitalization of $162.07 billion, a PE ratio of 37.70, a PEG ratio of 2.88 and a beta of 0.76. The company has a quick ratio of 1.25, a current ratio of 1.63 and a debt-to-equity ratio of 0.45. The stock’s 50 day moving average price is $216.32 and its 200-day moving average price is $197.35. Danaher has a twelve month low of $160.93 and a twelve month high of $242.80.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Wednesday, October 21st. The conglomerate reported $2.11 EPS for the quarter, beating analysts’ consensus estimates of $1.92 by $0.19. The company had revenue of $6.55 billion during the quarter, compared to the consensus estimate of $6.56 billion. Danaher had a return on equity of 11.17% and a net margin of 16.91%. Danaher’s revenue was up 8.3% on a year-over-year basis. During the same period last year, the business posted $1.89 earnings per share. On average, equities analysts anticipate that Danaher will post 8.59 EPS for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.40 per share. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. Danaher’s dividend payout ratio (DPR) is presently 26.19%.

Institutional Investors Weigh In On Danaher

A number of hedge funds have recently modified their holdings of DHR. Main Street Group LTD bought a new position in Danaher during the first quarter valued at $25,000. N.E.W. Advisory Services LLC purchased a new stake in Danaher in the second quarter worth $25,000. Marquette Asset Management LLC increased its position in Danaher by 192.1% in the third quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate’s stock worth $25,000 after buying an additional 73 shares during the last quarter. Evolution Wealth Management Inc. increased its position in Danaher by 208.0% in the first quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock worth $29,000 after buying an additional 104 shares during the last quarter. Finally, Field & Main Bank bought a new stake in shares of Danaher in the second quarter valued at $29,000. Institutional investors own 79.05% of the company’s stock.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher reported third-quarter adjusted earnings of $2.11 per share, above the $1.92 analyst consensus, while revenue reached approximately $6.55 billion. Revenue increased 8.3% year over year, and management raised its full-year 2026 adjusted EPS outlook. Danaher 3Q Net Up Sharply as Company Boosts 2026 Adjusted EPS View
• Positive Sentiment: Analysts raised their valuation targets following the results. TD Cowen and JPMorgan lifted targets to $270, Goldman Sachs raised its target to $275, Stifel increased its target to $260, and Robert W. Baird raised its target to $254. The firms maintained bullish ratings, including Buy, Overweight and Outperform. Danaher Analysts Raise Their Forecasts Following Better-Than-Expected Q3 Earnings
• Positive Sentiment: Management highlighted margin strength, improved execution and an increased focus on innovation and artificial intelligence, factors analysts viewed as supporting a better longer-term outlook. Danaher Earnings Call Highlights Margin Strength, AI Push
• Neutral Sentiment: Despite the earnings beat and higher targets, shares declined in the immediate post-results reaction, suggesting investors may have already priced in much of the improvement. A recent valuation comparison also frames DHR as a stock for investors weighing quality and growth against its relatively elevated valuation. Danaher Q3 Recap: Decent Results, Still A Hold
• Negative Sentiment: Danaher’s new CEO emphasized the need for better execution and innovation. TD Cowen cited tariff pressure and a cautious 2027 outlook, creating uncertainty beyond the raised 2026 guidance and helping explain why the stock did not fully respond to the strong quarterly report. Danaher Posts First Earnings Under New CEO

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.